ClearPoint Neuro, Inc. (CLPT) Tops Q3 EPS by 4c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
ClearPoint Neuro Reports Third Quarter 2022 Results
November 8, 2022 4:05 PM ESTSOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022.
Third Quarter Highlights
Reported quarterly revenue of $5.1 million, a 13% year-over-year increase;Partner PTC Therapeutics gene therapy treatment Upstaza was granted full marketing authorization by the European Commission. Upstaza will be administered with the Companys SmartFlow® Neuro... More